

# Association of Genetically Predicted Insomnia With Risk of Sepsis A Mendelian Randomization Study

Marianne S. Thorkildsen, MD; Lise T. Gustad, PhD; Randi M. Mohus, PhD; Stephen Burgess, PhD;  
Tom I. L. Nilsen, PhD; Jan K. Damås, PhD; Tormod Rogne, PhD

 Supplemental content

**IMPORTANCE** Insomnia has been associated with altered inflammatory response as well as increased risk of infections and sepsis in observational studies. However, these studies are prone to bias, such as residual confounding. To further understand the potential causal association between insomnia and sepsis risk, a 2-sample Mendelian randomization (MR) approach should be explored.

**OBJECTIVE** To evaluate whether genetically predicted insomnia is associated with risk of sepsis.

**DESIGN, SETTING, AND PARTICIPANTS** Two-sample MR was performed to estimate the association between genetically predicted insomnia and sepsis risk. Data were obtained from a genome-wide association study identifying 555 independent genetic variants ( $R^2 < 0.01$ ) strongly associated with insomnia ( $P < 5 \times 10^{-8}$ ). Sensitivity analyses were conducted to address bias due to pleiotropy and sample overlap, along with mediation analyses and sex-stratified analyses. The insomnia data set included 2.4 million individuals of European ancestry from the UK Biobank and 23andMe. For sepsis, 462 918 individuals of European ancestry from the UK Biobank were included. Data were extracted between February and December 2022 and analyzed between March 2022 and March 2023.

**EXPOSURE** Genetically predicted insomnia.

**MAIN OUTCOME AND MEASURE** Sepsis.

**RESULTS** There were 593 724 individuals with insomnia and 10 154 cases of sepsis. A doubling in the population prevalence of genetically predicted insomnia was associated with an odds ratio of 1.37 (95% CI, 1.19-1.57;  $P = 7.6 \times 10^{-6}$ ) for sepsis. Sensitivity analyses supported this observation. One-third of the association between genetically predicted insomnia and risk of sepsis was mediated through a combination of cardiometabolic risk factors for sepsis (body mass index, type 2 diabetes, smoking, or cardiovascular disease; overall proportion, 35.2%; 95% CI, 5.1-76.9). The association between insomnia and sepsis was more pronounced among women compared with men (women: odds ratio, 1.44; 95% CI, 1.24-1.68; men: OR, 1.10; 95% CI, 0.86-1.40).

**CONCLUSIONS AND RELEVANCE** The concordance between these findings and previous observational studies supports that insomnia is potentially causally associated with the risk of sepsis. Thus, insomnia is a potential preventable risk factor of sepsis that should be further investigated, also in non-European populations.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Marianne S. Thorkildsen, MD, Gemini Center for Sepsis Research and Institute of Circulation and Medical Imaging, NTNU, Prinsesse Kristinas gt 3, 9491 Trondheim, Norway (mariasth@ntnu.no).

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2023.2717  
Published online August 9, 2023.

Insomnia is the most common sleep disorder and is associated with numerous adverse health outcomes.<sup>1</sup> In particular, insomnia is associated with an altered immune function and elevated systemic levels of inflammatory markers.<sup>2</sup> Evidence also suggests that sleep deprivation may impact inflammatory activation more in women than in men.<sup>3</sup> The severity and outcome of an infection is closely linked to the ability of the immune system to efficiently eradicate pathogens without harming the host. In the case of a dysregulated immune response, sepsis can develop, with accompanying high morbidity and mortality.<sup>4</sup>

A recent observational study reported that insomnia increased the risk of bloodstream infection, a condition closely linked to sepsis.<sup>5</sup> Importantly, since insomnia and systemic infections may share common causes, the observed association between insomnia and infectious disease risk could be biased due to residual confounding. Mendelian randomization (MR) is a method that uses genetic variants as instruments for modifiable risk factors to reduce the influence of confounding and reverse causation.<sup>6</sup> This approach mimics a randomized clinical trial by using the principle of random allocation of genetic variants.

Our aim was to assess if insomnia is associated with risk of sepsis when applying instrumental variable analyses using genetic instruments. We also aimed to estimate the proportion of the association between genetically predicted insomnia and sepsis that is mediated through known cardiometabolic risk factors of sepsis, ie, body mass index (BMI), smoking, type 2 diabetes (T2D), and cardiovascular disease (CVD).

## Method

We used a 2-sample MR approach, following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for MR. Single-nucleotide variants (SNVs) were used as genetic instruments, and for each SNV, we calculated the Wald ratio, defined as the SNV-outcome association divided by the SNV-exposure association.<sup>6</sup> For an instrument to be valid, it must be associated with the exposure, cannot be associated with any confounder of the exposure-outcome association, and cannot affect the outcome other than through the exposure.<sup>6</sup>

Only individuals of European ancestry were included in this study, as other ancestry groups were not available for all traits of interest, and a mix of ancestries can induce confounding due to genetic population structure.<sup>6</sup> We obtained 555 genetic variants that were strongly associated ( $P < 5 \times 10^{-8}$ ) with insomnia and that were independent of one another ( $R^2 < 0.01$ ) from a genome-wide association study (GWAS) evaluating 2.4 million individuals from the UK Biobank and 23andMe (Table; Supplement 1).<sup>7</sup> For the multivariable MR analyses, we extracted genetic variants from relevant GWASs of BMI,<sup>8</sup> T2D,<sup>10</sup> smoking status,<sup>9</sup> and CVD.<sup>11</sup>

Genetic associations for sepsis were extracted from a GWAS in the UK Biobank including 10 154 sepsis cases and 452 764 controls (maximum 16% overlap with insomnia GWAS).<sup>12</sup> Cases were defined according to the explicit sepsis criteria defined

## Key Points

**Question** Is genetically predicted insomnia associated with risk of sepsis?

**Findings** In this mendelian randomization study including 593 724 individuals, a doubling in the genetically predicted prevalence of insomnia was significantly associated with a 37% increased risk of insomnia.

**Meaning** These findings support a potential causal association between insomnia and the risk of sepsis.

in the most recent Global Burden of Disease Study of Sepsis.<sup>4</sup> To validate our findings, and because sample overlap between the exposure and outcome GWASs may bias the estimate toward the confounded estimate, we included a sensitivity analysis of sepsis (*International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* code A41) in FinnGen (Table).<sup>11</sup>

In the main analysis, using the inverse-variance weighted (IVW) method, we calculated the combined association across the Wald ratios for all SNVs, putting more emphasis to the SNVs with the lowest variance. For the IVW estimate to be unbiased, all included instruments must be valid. Thus, we conducted sensitivity analyses using the weighted median, weighted mode, and MR-Egger regression that provide unbiased results even in the presence of some invalid instruments (eg, due to pleiotropy) but at the cost of lower statistical power.<sup>6</sup>

We evaluated the proportion of the association between insomnia and sepsis that was mediated through 4 strong cardiometabolic risk factors of sepsis: BMI, T2D, smoking, and CVD.<sup>8-11</sup> Using the SNVs identified as genetic instruments for insomnia, we calculated the direct association between insomnia and sepsis by conducting multivariable MR analyses with each of the 4 potential mediators at a time and then all mediators combined. The univariable analyses yielded the total association of genetically predicted insomnia. The proportion mediated was calculated as the direct association divided by the total association and subtracted from 1, and the SEs were estimated using bootstrapping.<sup>13</sup> Lastly, to assess possible effect modification by sex, we performed univariable IVW analysis using sex-specific estimates of genetic associations for insomnia with the same SNV-selection criteria as for the main analysis.


We used R version 4.0.5 (The R Foundation) for data formatting and the TwoSampleMR package version 0.5.6 and MendelianRandomization version 0.7.0 packages in R for all analyses (eAppendix in Supplement 2).<sup>14</sup> All estimates were multiplied by 0.693 (= ln 2) to present the results as per doubling in the prevalence of insomnia. All data used in this study were retrieved from studies that had sought informed consent from their study participants. We only used deidentified, publicly available, summary-level data, which does not constitute human subjects research per 45 CFR 46.102 and therefore did not require institutional review board approval.

**Table. Overview of Genome-Wide Association Studies Used**

Trait	Study	Cohorts	Phenotype definition	Population
<b>Exposure</b>				
Insomnia	Watanabe et al, <sup>7</sup> 2022	UK Biobank and 23andMe	<ul style="list-style-type: none"> <li>Cases: self-reported trouble falling asleep or self-reported diagnosis of insomnia</li> <li>Controls: not identified as cases (but had answered the questions)</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 593 724; female, 390 751; male, 222 753</li> <li>Controls: 1 771 286; female, 1 018 386; male, 993 280</li> </ul>
<b>Covariate</b>				
Body mass index	Pulit et al, <sup>8</sup> 2019	30 Cohorts, including UK Biobank	Measured body mass index at study participation	806 834
Smoking initiation	Liu et al, <sup>9</sup> 2019	26 Cohorts, including deCODE and UK Biobank	<ul style="list-style-type: none"> <li>Cases: self-reported smoking behavior</li> <li>Controls: never smoker</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 557 337</li> <li>Controls: 674 754</li> </ul>
T2D	Mahajan et al, <sup>10</sup> 2018	32 Cohorts, including 23andMe, deCODE and UK Biobank	<ul style="list-style-type: none"> <li>Cases: T2D status based on a combination of diagnostic testing (fasting glucose or HbA<sub>1c</sub>), recorded diagnosis codes, or self-report</li> <li>Controls: not diagnosed with T2D</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 74 124</li> <li>Controls: 824 006</li> </ul>
Cardiovascular disease	Kurki et al, <sup>11</sup> 2023	FinnGen release 8	<ul style="list-style-type: none"> <li>Cases: FinnGen code FG_CVD</li> <li>Controls: not classified as case</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 174 499</li> <li>Controls: 168 000</li> </ul>
<b>Outcome</b>				
Sepsis (main analysis)	Ponsford et al, <sup>12</sup> 2020	UK Biobank	<ul style="list-style-type: none"> <li>Cases: explicit sepsis diagnosis codes</li> <li>Controls: not classified as case</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 10 154</li> <li>Controls: 452 764</li> </ul>
Sepsis (sensitivity analysis)	Kurki et al, <sup>11</sup> 2023	FinnGen release 8	<ul style="list-style-type: none"> <li>Cases: FinnGen code ABI_OTHER_SEPSIS</li> <li>Controls: not classified as case</li> </ul>	<ul style="list-style-type: none"> <li>Cases: 10 666</li> <li>Controls: 303 314</li> </ul>


Abbreviations: HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; T2D, type 2 diabetes.

**Figure 1. Mendelian Randomization (MR) Analyses of the Association Between Genetically Predicted Insomnia and Risk of Sepsis**



Odds ratios (ORs) with 95% CIs of risk of sepsis per genetically predicted doubling of the prevalence of insomnia. The FinnGen analysis used data from FinnGen instead of UK Biobank and was analyzed using inverse-variance weighting.

**Figure 2. Proportion of the Association of Genetically Predicted Insomnia With the Risk of Sepsis Mediated Through Cardiometabolic Risk Factors**



BMI indicates body mass index; CVD, cardiovascular disease.

## Results

There were 593 724 individuals with insomnia and 10 154 cases of sepsis. The genetic variants used in the main analysis explained 3.9% of the variance of insomnia. A genetically predicted doubling in the prevalence of insomnia was associated with an odds ratio (OR) for sepsis of 1.37 (95% CI, 1.19-1.57;

$P = 7.6 \times 10^{-6}$ ) (Figure 1). The weighted mode, weighted median, and MR-Egger analyses all supported the main analysis. The main analysis was also supported by the analysis using sepsis data from FinnGen. One-third of the association between genetically predicted insomnia and risk of sepsis was mediated through BMI, T2D, smoking, or CVD (Figure 2) but with a likely direct association independent of these factors (OR, 1.23; 95% CI, 1.03-1.45;  $P = .02$ ). Considering each cardiometabolic

risk factor separately, only BMI significantly mediated the association between genetically predicted insomnia and risk of sepsis. Finally, the harmful consequence of insomnia was more pronounced among women compared with men (women: OR, 1.44; 95% CI, 1.24-1.68;  $P = 2.6 \times 10^{-6}$ ; men: OR, 1.10; 95% CI, 0.86-1.40;  $P = .44$ ).

## Discussion

Our findings support a potential causal association between genetically predicted insomnia and risk of sepsis. This is in line with previous research and results from observational data, reporting that insomnia increases the risk of altered immune response<sup>2,15</sup> and bloodstream infection.<sup>5</sup> We observed that much of the association between genetically predicted insomnia and risk of sepsis was mediated through BMI, T2D, CVD, or smoking. This is supported by studies reporting that these factors are potentially caused or worsened by insomnia<sup>15</sup> and are also potential causes of sepsis.<sup>12</sup> However, most of the association between insomnia and risk of sepsis was not explained by these factors, indicating that insomnia may have a substantial direct influence on sepsis risk.

Numerous studies have reported that insomnia alters immune function through various mechanisms, suggesting a link to immune and inflammatory dysregulation and thus also to elevated sepsis risk.<sup>2,15</sup> Interestingly, sleep deprivation is reported to cause a stronger inflammatory activation in women than men, which may explain the stronger effect of insomnia on sepsis risk in women than men observed in our study.<sup>3</sup>

## Strengths and Limitations

Our findings are strengthened by the consistent results across sensitivity analyses robust to pleiotropy and the evaluation in a separate outcome cohort with no overlap with the exposure GWAS. An important limitation to our study is that it only included individuals of European ancestry, and we encourage future studies to evaluate whether our findings replicate in other ancestry groups.

## Conclusions

The findings from this MR study are in accordance with those of previous observational studies and support a potential causal association between insomnia and risk of sepsis.

### ARTICLE INFORMATION

**Accepted for Publication:** May 12, 2023.

**Published Online:** August 9, 2023.  
doi:10.1001/jamapsychiatry.2023.2717

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/).  
© 2023 Thorkildsen MS et al. *JAMA Psychiatry*.

**Author Affiliations:** Gemini Center for Sepsis Research at Institute of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway (Thorkildsen, Gustad, Mohus, Damås); Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway (Gustad); Department of Medicine and Rehabilitation, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway (Gustad); Clinic of Anesthesia and Intensive Care, St Olavs Hospital, Trondheim, Norway (Mohus); MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom (Burgess); Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom (Burgess); Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway (Nilsen); Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway (Nilsen); Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway (Damås); Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (Damås); Department of Infectious Diseases, Clinic of Medicine, St Olavs Hospital, Trondheim, Norway (Damås); Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, Connecticut (Rogne).

**Author Contributions:** Dr Rogne had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Thorkildsen, Gustad, Mohus, Nilsen, Damås, Rogne.

**Acquisition, analysis, or interpretation of data:** Thorkildsen, Gustad, Burgess, Nilsen, Rogne.

**Drafting of the manuscript:** Thorkildsen, Mohus, Damås, Rogne.

**Critical review of the manuscript for important intellectual content:** Rogne.

**Statistical analysis:** Mohus, Rogne.

**Obtained funding:** Gustad, Damås, Rogne.

**Administrative, technical, or material support:** Thorkildsen, Damås, Rogne.

**Study supervision:** Gustad, Mohus, Nilsen, Damås, Rogne.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** Dr Burgess was funded by the Wellcome Trust and the United Kingdom Research and Innovation Medical Research Council.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See [Supplement 3](#).

### REFERENCES

1. Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. *Am J Manag Care*. 2020;26(4)(suppl):S76-S84. doi:10.37765/ajmc.2020.42769
2. Irwin MR. Sleep and inflammation: partners in sickness and in health. *Nat Rev Immunol*.

2019;19(11):702-715. doi:10.1038/s41577-019-0190-z

3. Irwin MR, Carrillo C, Olmstead R. Sleep loss activates cellular markers of inflammation: sex differences. *Brain Behav Immun*. 2010;24(1):54-57. doi:10.1016/j.bbi.2009.06.001

4. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7

5. Thorkildsen MS, Laugsand LE, Nilsen TIL, et al. Insomnia symptoms and risk of bloodstream infections: prospective data from the prospective population-based Nord-Trøndelag Health Study (HUNT), Norway. *J Sleep Res*. 2023;32(1):e13696. doi:10.1111/jsr.13696

6. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nat Rev Methods Primers*. 2022;2(1):7. doi:10.1038/s43586-021-00092-5

7. Watanabe K, Jansen PR, Savage JE, et al; 23andMe Research Team. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. *Nat Genet*. 2022;54(8):1125-1132. doi:10.1038/s41588-022-01124-w

8. Pulit SL, Stoneman C, Morris AP, et al; GIANT Consortium. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet*. 2019;28(1):166-174. doi:10.1093/hmg/ddy327

9. Liu M, Jiang Y, Wedow R, et al; 23andMe Research Team; HUNT All-In Psychiatry. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and

alcohol use. *Nat Genet.* 2019;51(2):237-244. doi:10.1038/s41588-018-0307-5

**10.** Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet.* 2018;50(11):1505-1513. doi:10.1038/s41588-018-0241-6

**11.** Kurki MI, Karjalainen J, Palta P, et al; FinnGen. FinnGen provides genetic insights from a well-phenotyped isolated population.

*Nature.* 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8

**12.** Ponsford MJ, Gkatzionis A, Walker VM, et al. Cardiometabolic traits, sepsis, and severe COVID-19: a mendelian randomization investigation. *Circulation.* 2020;142(18):1791-1793. doi:10.1161/CIRCULATIONAHA.120.050753

**13.** Hesterberg T. Bootstrap. *Comput Stat.* 2011;3(6):497-526. doi:10.1002/wics.182

**14.** Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife.* 2018;7:e34408. doi:10.7554/eLife.34408

**15.** Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease. *Physiol Rev.* 2019;99(3):1325-1380. doi:10.1152/physrev.00010.2018